SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
- Guggenheim 3rd Annual Healthcare Innovation Conference
Fireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ET
Location: Boston, MA - Stifel Healthcare Conference
Fireside Chat: Wednesday, November 11, 2026 at 10:00 a.m. ET
Location: New York, NY - UBS Global Biopharma Conference
Fireside Chat: Monday, November 16, 2026 at 12:00 p.m. GMT
Location: London, UK - Jefferies Global Healthcare Conference
Fireside Chat: Tuesday, November 17, 2026 at 10:30 a.m. GMT
Location: London, UK
Members of the Jade management team will host one-on-one investor meetings during the conferences.
A live webcast of each of the fireside chats will be available on the Events page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.
About Jade Biosciences, Inc.
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Jade Biosciences Contact
Zane Goodwin
IR@JadeBiosciences.com
Media@JadeBiosciences.com
